C3i Launches Precision Medicine Services, Connecting Biomarker Discovery to Real-World Patient Outcomes

Montreal CDMO expands beyond cell therapy manufacturing with companion diagnostics, therapeutic monitoring, and integrated patient support programs.

What if every patient received a therapy tailored to their unique biology?

That question, aligned with the aspirational promise of precision medicine, is now at the heart of what C3i Center Inc. does. The Montreal-based contract development and manufacturing organization (CDMO), already Canada’s only fully validated cGMP facility compliant with Health Canada and EMA regulations, has officially launched a dedicated Precision Medicine Services division.

The announcement marks a significant strategic expansion for C3i, extending its reach from the manufacturing floor to the full clinical and patient journey. The new offering spans three integrated service areas: companion diagnostics, therapeutic monitoring, and integrated patient support programs. These areas form an end-to-end pipeline that C3i describes as connecting “biomarker discovery to real-world patient outcomes.”

Identifying the Right Patients for the Right Therapies

At the foundation of C3i’s precision medicine offering is its companion diagnostics (CDx) service. Companion diagnostics are tests that identify which patients are most likely to benefit from a specific therapy, and regulatory agencies such as the FDA increasingly require a validated CDx as a condition of drug approval. C3i positions itself as an end-to-end CDx partner: designing, validating, and implementing testing programs in its accredited medical laboratory.

Its on-site technology portfolio includes:

• Digital PCR
• Next-generation sequencing (NGS)
• Multiplex immunoanalysis (ELISA, ELISPOT, Luminex)
• Molecular pathology
• Flow cytometry
• Biochemistry

These technologies are all available without external laboratory dependencies, enabling faster test development and shorter turnaround times.

Following the Patient’s Journey

Launching a therapy is only half of the challenge. C3i’s therapeutic monitoring service addresses what comes after: tracking immune reconstitution or transplanted cell persistence in the case of cell and gene therapies, and treatment-related biomarkers for any type of therapy to follow every patient’s evolution over time. Unlike traditional pharmacokinetic monitoring, this service is specifically designed to address the complexities inherent to a broad spectrum of therapies, from small molecules and biologics to cell and gene therapies, where questions about long-term efficacy and immunogenicity require a more sophisticated approach.

Clinical teams and pharma partners receive the longitudinal data needed to assess and improve therapeutic outcomes across any treatment modality, through a service suite that includes:

• Immune cell phenotyping
• Cytokine profiling
• Immune repertoire sequencing (TCRβ)
• Chimerism analysis
• Therapeutic drug monitoring (TDM) combined with anti-drug antibody (ADA) testing

Connecting Patients, Physicians, and Pharma Partners

A validated assay in an accredited laboratory, C3i acknowledges, is only the beginning. True precision medicine requires a continuous, operational link between the patient, the prescribing physician, and the pharmaceutical partner. This is what the company’s integrated patient support programs are designed to provide.

C3i’s multidisciplinary team of scientists, specialist physicians, patient care managers, and account managers will manage national sample-collection logistics, appointment booking, adverse-event reporting, physician and health professional support, and custom program management reporting.

What Sets C3i Center Apart

In a sector where precision medicine programs often span multiple vendors and organizations, C3i’s core differentiator is integration. The company brings together, under one roof:

• Clinical-grade assays validated in its accredited medical laboratory
• A full on-site technology portfolio: NGS, digital PCR, flow cytometry, multiplex immunoassays, enabling rapid development without external dependencies
• Integrated patient support from national sample collection through support by a qualified health professional
• A pharma partnership model built for commercial-scale deployment, with C3i acting as an extension of its clients’ teams from the first conversation through launch and beyond

“Precision medicine demands a partner who connects science, operations, and the patient’s experience into a single, seamless program,” the company stated at launch. “That’s what we’ve built.”

A Natural Evolution for Canada’s Leading Cell Therapy CDMO

The launch comes at a defining moment for C3i. The company achieved a landmark milestone in 2024, becoming the first Canadian CDMO to receive Health Canada regulatory approval for the commercial production of cell therapy medicines.

Precision medicine services are a natural extension of that trajectory. C3i has long operated at the intersection of science, manufacturing, and clinical application; the new division formalizes that expertise into a structured offering for pharmaceutical and biotech partners who need more than a testing service; they need a partner who understands the entire ecosystem from biomarker to bedside.

For pharmaceutical and biotech companies looking to build or scale a precision medicine program, C3i’s full-service offering is available here.